China News Service, July 3rd. Independent wealth management agency Haiyin Holdings (NASDAQ: HYW), and financial services and index provider FactSet (NYSE: FDS; NASDAQ: FDS), jointly released the "FactSet Haiyin Global Big Health Stock Index (FHGHC)" on July 1st, providing benchmarks and navigation for global investors' investment layout in the field of big health.
"FactSet Haiyin Global Big Health Stock Index" combines Haiyin Holdings' deep insights in the field of big health and Huishi's global leading index compilation technology. It selects 40 high-quality stocks from 19 major exchanges and 36 big health sub-industry around the world, forming an authoritative industry benchmark and investment benchmark in the field of big health in the world.
"FactSet Haiyin Global Big Health Stock Index" component includes leading global medical and health companies such as Johnson & Johnson , Pfizer , Novartis , AstraZeneca , Thermo Fisher SW, HCA, Takeda Pharmaceuticals, 1 Sangong and other leading global medical and health companies. These constituent stocks are widely distributed in regions, with diverse business models, with market value exceeding US$1 billion and daily trading volume exceeding US$5 million. They are a compilation of blue chip stock in the global big health industry.
"FactSet Haiyin Global Big Health Stock Index" can be used as performance standards for global active management of big health fund managers; as the basic index for issuing big health ETFs; it will also be a comprehensive indicator for global analysts and institutional investors to see through the trends and performance of the global big health industry.
At the launch ceremony of the "FactSet Haiyin Global Big Health Stock Index", Ms. Wang Dian, President of Haiyin Holdings, said: "In the post-epidemic era, the medical, health and elderly care issues faced by mankind have become more urgent. How to introduce high-quality funds into excellent big health companies and promote the innovation and application of health technology has become the issue of the era of the global investment community. The "FactSet Haiyin Global Big Health Stock Index" launched by Haiyin and Huijin this time is to become a bridge between high-quality investors and high-quality big health companies around the world. Through the cooperation of capital and technology, answer the problem. The health and medical challenges faced by society and contribute health value to the people." Xiao Wen, vice president of Haiyin Holdings, said: "For Haiyin's global customers, the 'FactSet Haiyin Global Big Health Stock Index' is a prism for a systematic understanding of various sub-industry, various business models and leading companies of global big health. This will help Haiyin customers expand their professional understanding of the health industry, enhance their ability to judge investment opportunities in the health industry, and capture value from the big health super cycle in the post-epidemic era." Jeremy, head of global index business of
Huijin Zhou said: "In addition, the 'FactSet Haiyin Global Big Health Stock Index' can allow Asian investors to have a deeper understanding of the advanced concepts such as ' index investment , trend investment', and so on to practice long-term investment, cross-cycle investment, and multi-industry full allocation investment, and accumulate considerable wealth in the time track Snowball . As Asian investors allocate wealth to more and more industries and themes, index-based solutions will become an increasingly important portfolio construction tool."
"FactSet Haiyin Global Big Health Stock Index" was first released from July 1, 2022, and will be updated daily and released on global financial media, financial data terminals, stock broker platforms for use by global fund managers, ETF managers, institutional investors, high net worth clients, wealth management institutions, etc. ( China News Service APP)
